|

Poly-ICLC Clinical Trials

4 actively recruiting trials across 4 locations

No change since July 2026

Also known as: Hiltonol, Poly I:Poly C with Poly-L-Lysine Stabilizer, PolyI:PolyC with Poly-L-Lysine Stabilizer, Polyinosinic-Polycytidylic Acid Stabilized with Polylysine and Carboxymethylcellulose, Polyriboinosinic-Polyribocytidylic Acid-Polylysine Carboxymethylcellulose +2 more

Pipeline

Phase 1: 3Phase 2: 1

Top Sponsors

  • Washington University School of Medicine1
  • National Cancer Institute (NCI)1
  • Marina Kremyanskaya1
  • Fred Hutchinson Cancer Center1

Indications

Orange, California1 trial

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

UC Irvine Health/Chao Family Comprehensive Cancer Center

Phase 2

Orlando, Florida1 trial

Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease

AdventHealth

Phase 1

New York, New York1 trial

Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm

Icahn School of Medicine at Mount Sinai

Phase 1

Seattle, Washington1 trial

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer

Fred Hutch/University of Washington Cancer Consortium

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.